Panacea Pharmaceuticals Inc. presented its paper, "Improved Detection of Cancer Specific Serum Exosomal Aspartyl (Asparaginyl) beta Hydroxylase," and its findings on the company's multi-cancer HAAH exosome detection assay during the annual American Association for Cancer Research meeting in Washington, D.C. April 1-5.
The biomarker HAAH is proving to be useful in regards to diagnosing cancer cells as well as their activity.
"We are excited to report our continued advances in the understanding of the role of serum exosomes in the detection and monitoring of cancer," Panacea CEO and Chief Scientific Officer Hossein Ghanbari said.
Exosomes are said to be nanoparticles which serve as biomarkers, increasing the information about the cancer and the time available to treat it.
Panacea Pharmaceuticals, Inc., is a biopharmaceutical company, aimed as creating new cancer therapy options, as well as diagnostics for medical requirements that are often forgotten.
Panacea Pharmaceuticals shares news about cancer biomarkers
Alerts Sign-up